Please login to the form below

Not currently logged in
Email:
Password:

Excellence in Healthcare Collaboration and Partnerships

Sponsored by

Finalist

Abbott's Small Steps to Change programme in collaboration with NHS rheumatologists to implement Treat to Target

Abbott Laboratories in association with DNA Medical Communications


Summary of work

The Treat to Target principles in rheumatoid arthritis include early referral, regular assessment and early diagnosis to make disease remission a realistic target for patients.

Evidence shows that earlier treatment improves patient outcomes. However, access to biologics, if appropriate, is often delayed as they are second‐line treatment and patients are often not reviewed regularly enough or treated to a target, which can make treatment decisions subjective. 

Abbott UK rolled‐out Treat to Target nationally to improve the management of patients, and improve the access to biologics for patients who require this treatment. Partnership with the most influential UK KOLs (including the 2011 European Rheumatology Professional Body (EULAR) chair) led to the inclusion of Treat to Target in the latest SIGN guidance and publication of a consensus on standardising assessment using DAS28 in a peer‐reviewed journal. 

Treat to Target was delivered through a revolutionary programme, Small Steps to Change (SSTC), allowing rheumatologists to break change into small steps, through low-/no-cost solutions delivering target‐driven regimens. SSTC changed routine practice in over 40 units with huge improvements in referral rates (10.76 to two weeks), assessment completion rates (16.7 per cent to 78.9‐100 per cent) and fewer patients with high disease activity at referral (40 per cent vs 25 per cent).

 

 

Executive summary as submitted


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics